alvelestat
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 5, 2018 (NCT03636347)
Timeline
Indications
Mechanism of action
- Leukocyte elastaseINHIBITOR
ELANE inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1- Mol. weight
- 545.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3617964 ↗
Also known as
- alvelestat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03986086 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | Duke University, Mereo BioPharma, National Center for Advancing Translational Science (NCATS) |
| NCT04539795 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2020 | Mereo BioPharma, University of Alabama, Birmingham |
| NCT03679598 | Phase 2 | Nov 30, 2018 | Mereo BioPharma, National Institutes of Health (NIH), University of Alabama, Birmingham |
| NCT03636347 | Phase 2 | Oct 5, 2018 | Mereo BioPharma, Syneos Health, University of Birmingham |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 4 | 1 | 1 | 2018 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Center for Advancing Translational Science (NCATS) | Government | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2018 |
| Syneos Health | For profit | 1 | 0 | 1 | 2018 |
| University of Birmingham | Academic/Hospital | 1 | 0 | 1 | 2018 |
7 organizations
Page 1 / 1